What Has Been the Growth of the Inflammatory Bowel Disease Treatment Market So Far?
The inflammatory bowel disease treatment market has seen considerable growth due to a variety of factors.
• Over the past few years, the market size for inflammatory bowel disease treatment has seen robust growth. It is predicted to expand from $25.26 billion in 2024 to $27.45 billion in 2025, with a compound annual growth rate (CAGR) of 8.6%.
This growth during the historical period is due to several factors including a rise in the incidence of inflammatory bowel disease, increased demand for biologics and immunomodulators, advances in treatment methods, a growing elderly population, and heightened awareness of the disease.
What Are the Future Growth Projections for the Inflammatory Bowel Disease Treatment Market?
The inflammatory bowel disease treatment market is expected to maintain its strong growth trajectory in upcoming years.
• Expectations are high for a swift expansion in the inflammatory bowel disease treatment market in the following years. The market is predicted to achieve a growth of $40.27 billion by 2029, with a compound annual growth rate (CAGR) of 10.1%.
The surging expansion in the forecast period can be credited to the escalating investments in research and developmental endeavors, the growing appetite for biosimilars, the increasing prevalence of inflammatory bowel disease in newly industrialized markets, increased interest in personalized medicine, and the application of precision medicine in IBD treatment. Key trends in the forecast period encompass an increasing volume of product launches and approvals, customized dosing and treatment strategies in IBD management, the application of telemedicine for distance monitoring of IBD patients, exploration of microbiome-focused therapies for IBD, and the adoption of value-focused care models in IBD treatment.
What Factors Are Driving Growth In The Inflammatory Bowel Disease Treatment Market?
The escalating instances of Crohn's disease and ulcerative colitis are significantly propelling the growth of the inflammatory bowel disease treatment market. Crohn’s disease and ulcerative colitis are variants of inflammatory bowel diseases (IBD) resulting in inflammation and sores or ulcers in the digestive tracts. The upsurge in cases of Crohn’s disease and ulcerative colitis is projected to escalate demand for inflammatory bowel disease therapies, which are extensively employed to reduce intestinal inflammation and minimize or avert medical complications. For illustration, based on research published in the US National Library of Medicine in March 2022, it was revealed that approximately 1.6 million Americans are living with inflammatory bowel disease (Crohn's disease or ulcerative colitis) at present, and around 70,000 fresh cases of IBD are diagnosed annually in the USA. Consequently, the escalating incidents of Crohn's disease and ulcerative colitis are forecasted to stimulate the growth of the inflammatory bowel disease treatment market.
What Are The Main Segments Of The Global Inflammatory Bowel Disease Treatment Market?
The inflammatory bowel disease treatment market covered in this report is segmented –
1) By Drug Class: Aminosalicylates, Corticosteroids, TNF inhibitors, IL inhibitors, Anti-integrin, JAK inhibitors, Other Drug Classes
2) By Type: Crohn's Disease, Ulcerative Colitis
3) By Route Of Administration: Oral, Injectable
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Aminosalicylates: Mesalamine, Sulfasalazine, Balsalazide
2) By Corticosteroids: Prednisone, Budesonide, Hydrocortisone
3) By TNF Inhibitors: Infliximab, Adalimumab, Certolizumab pegol
4) By IL Inhibitors: Ustekinumab, Guselkumab
5) By Anti-Integrin: Vedolizumab, Natalizumab
6) By JAK Inhibitors: Tofacitinib, Filgotinib
7) By Other Drug Classes: Antibiotics, Immunosuppressants, Other Novel Therapies
Pre-Book The Inflammatory Bowel Disease Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Inflammatory Bowel Disease Treatment Market?
A significant trend gaining traction in the inflammatory bowel disease treatment market is the advent of technological improvement. Prominent corporations participating in this market are channeling their efforts towards AI-powered registries to maintain a competitive advantage. For example, in May 2024, Verantos, a real-world evidence (RWE) firm based in California, introduced the Inflammatory Bowel Disease Pragmatic Registry. This registry, enhanced by advanced artificial intelligence, produces top-notch real-world evidence (RWE) for ulcerative colitis and Crohn's disease. The goal of the registry is to expedite the creation of efficient therapies by offering an extensive dataset with more than 3 billion data points pertaining to patient care. This allows researchers from the biopharmaceutical field gather in-depth understanding of disease severity, treatment efficacy and clinical outcomes using both organized and random data from electronic health records.
Who Are the Key Players in the Inflammatory Bowel Disease Treatment Market?
Major companies operating in the inflammatory bowel disease treatment market include:
• AbbVie Inc.
• Biogen Inc.
• Johnson & Johnson
• Amgen Inc.
• Advanced Gastroenterology and Surgery Associates P. A.
• Atlanta Gastroenterology Associates LLC
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Cedars-Sinai Medical Center
• Celgene Corporation
• Cleveland Clinic Foundation
• Digestive Disease Associates of Rockland P. C.
• Eli Lilly and Company
• Gastrointestinal Specialists Inc.
• Gilead Sciences Inc.
• GlaxoSmithKline plc
• Illinois Gastroenterology Group LLC
• The Johns Hopkins Hospital Inc.
• Massachusetts General Hospital
• Mayo Clinic
• Merck & Co. Inc.
• Mount Sinai Health System Inc.
• Novartis International AG
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd
• Takeda Pharmaceutical Company Limited
• Texas Digestive Disease Consultants P. A.
• The Oregon Clinic - Gastroenterology West P. C.
• Salix Pharmaceuticals Inc.
• Vifor Pharma AG
• Zydus Pharmaceuticals (USA) Inc.
What Is The Most Dominant Region In The Inflammatory Bowel Disease Treatment Market?
North America was the largest region in the inflammatory bowel disease treatment market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inflammatory bowel disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
